set2 cell line bearing jak2v617f mutation (DSMZ)
DSMZ is a verified supplier 
94
Structured Review
DSMZ
set2 cell line bearing jak2v617f mutation
Set2 Cell Line Bearing Jak2v617f Mutation, supplied by DSMZ, used in various techniques. Bioz Stars score: 94/100, based on 129 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/set2+cell+line+bearing+jak2v617f+mutation/SET-2/pm28331226-75-1-25
Average 94 stars, based on 129 article reviews
Set2 Cell Line Bearing Jak2v617f Mutation, supplied by DSMZ, used in various techniques. Bioz Stars score: 94/100, based on 129 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/set2+cell+line+bearing+jak2v617f+mutation/SET-2/pm28331226-75-1-25
Average 94 stars, based on 129 article reviews
set2 cell line bearing jak2v617f mutation - by Bioz Stars,
2026-09
94/100 stars
Images
Related Articles
Mutagenesis:Article Title: The histone deacetylase inhibitor givinostat (ITF2357) exhibits potent anti-tumor activity against CRLF2-rearranged BCP-ALL. Article Snippet: Leukemias bearing CRLF2 and JAK2 gene alterations are characterized by aberrant JAK/STAT signaling and poor prognosis.. The HDAC inhibitor givinostat/ITF2357 has been shown to exert antineoplastic activity against both systemic juvenile idiopathic arthritis and myeloproliferative neoplasms through inhibition of the JAK/STAT pathway.. These findings led us to hypothesize that givinostat might also act against CRLF2-rearranged BCP-ALL, which lack effective therapies. Positive Control:Article Title: The histone deacetylase inhibitor givinostat (ITF2357) exhibits potent anti-tumor activity against CRLF2-rearranged BCP-ALL. Article Snippet: Leukemias bearing CRLF2 and JAK2 gene alterations are characterized by aberrant JAK/STAT signaling and poor prognosis.. The HDAC inhibitor givinostat/ITF2357 has been shown to exert antineoplastic activity against both systemic juvenile idiopathic arthritis and myeloproliferative neoplasms through inhibition of the JAK/STAT pathway.. These findings led us to hypothesize that givinostat might also act against CRLF2-rearranged BCP-ALL, which lack effective therapies. Negative Control:Article Title: The histone deacetylase inhibitor givinostat (ITF2357) exhibits potent anti-tumor activity against CRLF2-rearranged BCP-ALL. Article Snippet: Leukemias bearing CRLF2 and JAK2 gene alterations are characterized by aberrant JAK/STAT signaling and poor prognosis.. The HDAC inhibitor givinostat/ITF2357 has been shown to exert antineoplastic activity against both systemic juvenile idiopathic arthritis and myeloproliferative neoplasms through inhibition of the JAK/STAT pathway.. These findings led us to hypothesize that givinostat might also act against CRLF2-rearranged BCP-ALL, which lack effective therapies. |